BIIB:NSD-Biogen Inc (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 176.93

Change

+3.41 (+1.97)%

Market Cap

USD 25.32B

Volume

2.46M

Analyst Target

USD 305.39
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-05 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

-5.16 (-7.22%)

USD 221.48B
AMGN Amgen Inc

+2.38 (+0.75%)

USD 171.55B
SNY Sanofi ADR

-0.10 (-0.19%)

USD 134.67B
GILD Gilead Sciences Inc

+0.38 (+0.42%)

USD 111.44B
GRFS Grifols SA ADR

+0.49 (+5.57%)

USD 6.92B
AMRN Amarin Corporation PLC

+0.02 (+3.06%)

USD 0.25B
MIRA MIRA Pharmaceuticals, Inc. Com..

+0.02 (+1.08%)

USD 0.03B
SCLX Scilex Holding Company

+0.09 (+8.83%)

N/A
SCLXW Scilex Holding Company

N/A

N/A

ETFs Containing BIIB

UBIO 6.30 % 0.95 %

N/A

N/A
BIS ProShares UltraShort Nasd.. 6.12 % 0.95 %

-0.31 (0.30%)

USD 3.52M
XY7D:XETRA Global X S&P 500® Covere.. 5.61 % 0.00 %

+0.03 (+0.30%)

N/A
XYLU:LSE Global X S&P 500® Covere.. 4.50 % 0.00 %

+0.07 (+0.30%)

USD 0.03B
BBH VanEck Biotech ETF 4.15 % 0.35 %

+2.80 (+0.30%)

USD 0.43B
BTEC:SW iShares Nasdaq US Biotech.. 3.51 % 0.00 %

+0.06 (+0.30%)

N/A
USMV:LSE Ossiam US Minimum Varianc.. 2.67 % 0.00 %

+1.85 (+0.30%)

USD 0.01B
MVUS:PA 2.67 % 0.00 %

N/A

N/A
SPMV:PA 2.67 % 0.00 %

N/A

N/A
IBBQ Invesco Nasdaq Biotechnol.. 2.59 % 0.00 %

+0.26 (+0.30%)

USD 0.04B
2B70:F iShares NASDAQ US Biotech.. 2.58 % 0.00 %

N/A

USD 0.52B
2B70:XETRA iShares Nasdaq US Biotech.. 2.58 % 0.00 %

-0.03 (0.30%)

USD 0.52B
CURE:AU ETFS S&P Biotech ETF 2.52 % 0.00 %

-0.04 (0.30%)

USD 0.04B
MRND 2.44 % 0.00 %

N/A

N/A
BIB ProShares Ultra Nasdaq Bi.. 1.88 % 0.95 %

+1.24 (+0.30%)

USD 0.08B
VCSH Vanguard Short-Term Corpo.. 0.08 % 0.07 %

+0.05 (+0.30%)

USD 35.54B
SCHZ Schwab U.S. Aggregate Bon.. 0.01 % 0.04 %

+0.05 (+0.30%)

USD 8.38B
FLAG 0.00 % 1.52 %

N/A

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

+2.21 (+0.30%)

USD 7.19B
MXDU 0.00 % 0.34 %

N/A

N/A
DQML 0.00 % 0.00 %

N/A

N/A
JAGG 0.00 % 0.07 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.02 (0.30%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.04 (0.30%)

N/A
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

-0.05 (0.30%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.01 (0.30%)

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

+1.40 (+0.30%)

N/A
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

+0.96 (+0.30%)

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

+0.01 (+0.30%)

N/A
LUMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.00 %

+37.50 (+0.30%)

N/A
XMWD:LSE Xtrackers MSCI World Swap.. 0.00 % 0.00 %

+0.72 (+0.30%)

N/A
CEM2:F 0.00 % 0.00 %

N/A

N/A
OSX2:F Ossiam Lux - Ossiam US Mi.. 0.00 % 0.00 %

+0.40 (+0.30%)

N/A
CEM2:XETRA 0.00 % 0.00 %

N/A

N/A
OSX2:XETRA Ossiam US Minimum Varianc.. 0.00 % 0.00 %

+1.30 (+0.30%)

USD 0.12B
BIOT 0.00 % 0.00 %

N/A

N/A
HEAL:SW iShares Healthcare Innova.. 0.00 % 0.00 %

+0.02 (+0.30%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -31.63% 40% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.63% 40% F 24% F
Trailing 12 Months  
Capital Gain -27.96% 50% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.96% 50% F 23% F
Trailing 5 Years  
Capital Gain -38.32% 57% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.32% 57% F 30% F
Average Annual (5 Year Horizon)  
Capital Gain -3.77% 60% D- 30% F
Dividend Return -3.77% 60% D- 28% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 24.70% 50% F 71% C-
Risk Adjusted Return -15.26% 60% D- 26% F
Market Capitalization 25.32B 50% F 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector